Lexington Biosciences Inc.

LNB on CSEToday's ChangeVolume52 Week Range (Low/Hi)Market Cap
0.60CAN 0.02/3.45%200,4530.27 / 0.6221.00 M
LXGTF on OTCQBToday's ChangeVolume52 Week Range (Low/Hi)Market Cap
0.48US 0.01/2.78%227,8630.25 / 0.4816.70 M

Contact Information

Lexington Biosciences Inc.

Headquarters:
5470 Kietzke Lane, Suite 300
Reno, Nevada
USA, 89511
Tel: 1 (800) 320-2640
Email: Send a message
Website: Visit website
For more information...
Lead: Laura Welsh
Dec 11, 2017 - 12:00 PM CST Corporate Presentation - Dallas
Dec 12, 2017 - 1:00 PM PST Corporate Presentation - San Francisco
Jan 15, 2018 - 12:00 PM MST Corporate Presentation - Calgary
Jan 16, 2018 - 1:00 PM PST Corporate Presentation - Vancouver

Lexington Biosciences is a medical device company developing the HeartSentry, a new non-invasive diagnostic device to measure and monitor cardiovascular health by assessing the function of a person’s vascular endothelium — the vital innermost lining of a person’s cardiovascular system. Currently, the standard of care is measurement using expensive external ultrasound by a highly trained technician. The HeartSentry core technology was developed at the University of California Berkeley over a fifteen-year R&D period involving many research studies and product iterations resulting in portfolio of multiple pending and issued patents licensed to the company. By taking delivery of the clinical trial ready HeartSentry units the company will commence studies as soon as possible. Our aim is to make HeartSentry accurate, quick, and cost effective so it can become the standard of care for cardiologists, general practitioners, and ultimately patients for first line evaluation of a person’s cardiovascular health. Lexington is engaged with the US FDA and other regulatory agencies on the required product approvals for the HeartSentry.

Eric Willis - President

Jonathan S. Maltz, PhD. - Chief Scientific Advisor

Donald A. McInnes - Advisor

Doug Janzen - Chairman

Rocco Rossi - Director

Bryan Disher - Director (Audit Committee)

Stock Information

Events

Dec 11, 2017 - 12:00 PM CST Corporate Presentation - Dallas
Dec 12, 2017 - 1:00 PM PST Corporate Presentation - San Francisco
Jan 15, 2018 - 12:00 PM MST Corporate Presentation - Calgary
Jan 16, 2018 - 1:00 PM PST Corporate Presentation - Vancouver

Company Overview

Lexington Biosciences is a medical device company developing the HeartSentry, a new non-invasive diagnostic device to measure and monitor cardiovascular health by assessing the function of a person’s vascular endothelium — the vital innermost lining of a person’s cardiovascular system. Currently, the standard of care is measurement using expensive external ultrasound by a highly trained technician. The HeartSentry core technology was developed at the University of California Berkeley over a fifteen-year R&D period involving many research studies and product iterations resulting in portfolio of multiple pending and issued patents licensed to the company. By taking delivery of the clinical trial ready HeartSentry units the company will commence studies as soon as possible. Our aim is to make HeartSentry accurate, quick, and cost effective so it can become the standard of care for cardiologists, general practitioners, and ultimately patients for first line evaluation of a person’s cardiovascular health. Lexington is engaged with the US FDA and other regulatory agencies on the required product approvals for the HeartSentry.

Management

Eric Willis - President

Jonathan S. Maltz, PhD. - Chief Scientific Advisor

Donald A. McInnes - Advisor

Board of Directors

Doug Janzen - Chairman

Rocco Rossi - Director

Bryan Disher - Director (Audit Committee)

Contact Information

Headquarters:
5470 Kietzke Lane, Suite 300
Reno, Nevada
89511, USA
Telephone: 1 (800) 320-2640
Email: Send a message
Website: Visit website